BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines accumulated Amortization — Finite-Lived Intangible Assets ($M) ($M)
Form 10-Q / 10-K Intangible Assets Note (XBRL)
Latest, Q2 2026
27.5
Period ended Jun 30, 2026
Change on a year earlier
+34.8%
20.4 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accumulated Amortization — Finite-Lived Intangible Assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 27.5 | +34.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 25.7 | +16.8% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 23.8 | +14.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 22 | +10.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 20.4 | +10.9% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 22 | +27.9% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 20.8 | +29.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 19.9 | +51.9% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 18.4 | +70.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 17.2 | +73.7% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 16.1 | +80.9% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 13.1 | +65.8% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 10.8 | +54.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 9.90 | +65.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 8.90 | +78.0% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 7.90 | +88.1% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 7 | +84.2% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 6 | +71.4% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 5 | +51.5% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 4.20 | +35.5% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 3.80 | +31.0% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 3.50 | +25.0% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 3.30 | +32.0% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 3.10 | +47.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 2.90 | +61.1% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 2.80 | +86.7% | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2019 | Dec 31, 2019 | 2.50 | +127.3% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 2.10 | +162.5% | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2019 | Jun 30, 2019 | 1.80 | +200.0% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 1.50 | +275.0% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 1.10 | +450.0% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 0.80 | +700.0% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 0.60 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 0.40 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 0.20 | – | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2017 | Sep 30, 2017 | 0.10 | – | 10-Q FY2017 (XBRL) ↗ |
Breakdown
What makes up accumulated amortization — finite-lived intangible assets ($m)
Cite this data
StockData. (2026). BeOne Medicines Accumulated Amortization — Finite-Lived Intangible Assets ($M) ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/intang_accum_tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.